KNT-127

KNT-127 is a D1 receptor partial agonist that is under investigation for the treatment of schizophrenia and Parkinson's disease. It is being developed by Kyowa Hakko Kirin, a Japanese pharmaceutical company.

History

KNT-127 was first synthesized by researchers at Kyowa Hakko Kirin. The compound was identified as a potential therapeutic agent due to its unique pharmacological profile. It is a partial agonist at the D1 receptor, meaning it can both activate and inhibit this receptor depending on the physiological context. This makes it a promising candidate for the treatment of disorders characterized by dysregulated dopamine signaling, such as schizophrenia and Parkinson's disease.

Pharmacology

KNT-127 is a partial agonist at the D1 receptor, one of the five subtypes of dopamine receptors in the brain. This receptor is primarily expressed in the prefrontal cortex, a brain region implicated in cognitive functions such as working memory and decision making. Dysregulation of D1 receptor signaling has been implicated in several neuropsychiatric disorders, including schizophrenia and Parkinson's disease.

In preclinical studies, KNT-127 has been shown to enhance cognitive function and reduce psychotic symptoms in animal models of schizophrenia. It has also been shown to improve motor symptoms in animal models of Parkinson's disease. These findings suggest that KNT-127 may have therapeutic potential in these disorders.

Clinical Development

KNT-127 is currently in the early stages of clinical development. Phase I clinical trials have been completed, and the drug has been shown to be safe and well-tolerated in healthy volunteers. Phase II trials are currently underway to evaluate the efficacy of KNT-127 in patients with schizophrenia and Parkinson's disease.

Future Directions

If the ongoing clinical trials are successful, KNT-127 could represent a new treatment option for patients with schizophrenia and Parkinson's disease. However, further research is needed to fully understand the therapeutic potential of this compound.

- Weight loss injections in NYC (generic and brand names):
- Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.

NYC weight loss doctor appointments

Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.

Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC

Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.